Turning Point Therapeutics Competitors

Grifols (NASDAQ:GRFS) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Grifols and Turning Point Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

Grifols has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Grifols and Turning Point Therapeutics, as reported by MarketBeat.com.

Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Turning Point Therapeutics is more favorable than Grifols.

Institutional & Insider Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Grifols and Turning Point Therapeutics' gross revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats Turning Point Therapeutics on 7 of the 13 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Turning Point Therapeutics' gross revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Dr. Reddy's Laboratories and Turning Point Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Dr. Reddy's Laboratories and Turning Point Therapeutics, as reported by MarketBeat.com.

Dr. Reddy's Laboratories currently has a consensus price target of $70.00, suggesting a potential downside of 2.06%. Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' higher possible upside, analysts clearly believe Turning Point Therapeutics is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats Turning Point Therapeutics on 7 of the 12 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Teva Pharmaceutical Industries and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Turning Point Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Teva Pharmaceutical Industries and Turning Point Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Teva Pharmaceutical Industries and Turning Point Therapeutics, as reported by MarketBeat.

Teva Pharmaceutical Industries currently has a consensus target price of $11.7778, suggesting a potential upside of 14.68%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Teva Pharmaceutical Industries.

Summary

Turning Point Therapeutics beats Teva Pharmaceutical Industries on 7 of the 13 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Jazz Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Jazz Pharmaceuticals and Turning Point Therapeutics, as reported by MarketBeat.

Jazz Pharmaceuticals currently has a consensus target price of $192.6250, suggesting a potential upside of 9.51%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Turning Point Therapeutics on 9 of the 13 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bausch Health Companies and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Turning Point Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bausch Health Companies and Turning Point Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bausch Health Companies and Turning Point Therapeutics, as reported by MarketBeat.

Bausch Health Companies currently has a consensus target price of $34.80, suggesting a potential upside of 24.64%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Bausch Health Companies.

Summary

Turning Point Therapeutics beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Turning Point Therapeutics (NASDAQ:TPTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Turning Point Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Maravai LifeSciences and Turning Point Therapeutics, as reported by MarketBeat.

Maravai LifeSciences currently has a consensus target price of $38.3750, suggesting a potential upside of 6.07%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 133.11%. Given Turning Point Therapeutics' higher possible upside, analysts plainly believe Turning Point Therapeutics is more favorable than Maravai LifeSciences.

Institutional and Insider Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Maravai LifeSciences and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.